HEKMA is the only platform that gives PAGs genuine power, real-time transparency, and direct influence in the clinical research ecosystem β permanently free for the organisations that represent patients.
52
PAG partners
50+
PAG flags resolved
100%
Core tools free
14
Trials in your area
4
Awaiting your input
127
Member referrals
We Hear You
Sponsors launch trials in our disease area without notifying us. Our members find out months later β or not at all.
Trial protocols are written without PAG input. The result: endpoint designs that don't reflect what patients actually care about.
Data reaches PAGs years after trial completion β too late to inform patient decisions, advocacy strategy, or member communication.
Sponsors recruit through our lists and networks but rarely share insights, results, or revenue with the organisations that made it possible.
When sponsors misrepresent trial burden or fail to engage patients appropriately, PAGs have no formal mechanism to raise the concern publicly.
HEKMA does the operational work: routing requests, tracking communications, maintaining dashboards, and surfacing relevant trials automatically.
What HEKMA Gives PAGs
Live view of every trial in your disease area β including sponsor names, PAG involvement status, and open flags.
Formally request protocol review on any trial. HEKMA routes your request directly to the sponsor and tracks their response publicly.
Co-branded patient referral links tracked back to your PAG. See how many of your members applied, screened, and enrolled.
Your own moderated community space on HEKMA, co-branded with your PAG identity. You own the content. You set the rules.
Endorse trials that meet your standards. Flag trials that don't. Your flags are public. Sponsors must respond. Every flag is permanent.
HEKMA is sponsor-funded. Core PAG tools are permanently free. We will never charge the organisations that represent patients.
Hero Product
The only product of its kind in the global clinical trial industry. Live, public visibility into every sponsor trial β who's involved, who's been excluded, and who has raised a flag.
Use Case 01
The Epilepsy Foundation discovered 4 Phase III trials in their disease area where they had zero involvement. They used HEKMA to formally request PAG consultation on all four.
Use Case 02
A PAG flagged a trial for inadequate patient-burden disclosure. The flag appeared publicly on the trial listing. The sponsor responded within 14 days and updated their protocol summary.
Use Case 03
After reviewing protocol design, a diabetes PAG formally endorsed a trial. Patient applications to that trial increased 34% within 30 days of the endorsement appearing on the listing.
| Trial Title | Sponsor | Phase | PAG Involvement | Referrals | Flags | Action |
|---|---|---|---|---|---|---|
CBD Adjunctive Therapy in Drug-Resistant Epilepsy | GW Pharmaceuticals | Phase III | Advisory Board | 127 | β | |
Tirzepatide for Type 2 Diabetes β UAE Cohort | Eli Lilly | Phase III | Participating | 84 | β | |
Gene Therapy for Sickle Cell Disease | bluebird bio | Phase II | Invited | 23 | π© 1 | |
Lecanemab for Early Alzheimer's Disease | Eisai / Biogen | Phase III | None | β | π© 2 | |
Upadacitinib for Rheumatoid Arthritis | AbbVie | Phase IV | Participating | 61 | β |
Full Feature Set
| Product / Feature | Cost to PAG |
|---|---|
π‘PAG Transparency Dashboard | Free |
π
Trial Endorsement & Flag System | Free |
πProtocol Review Request Tool | Free |
πPatient-PAG Matching | Free |
π¬Co-Branded Community Group | Free (basic) / Paid (white-label) |
πMember Analytics | Paid |
πReferral Link Generator | Free |
π€Ask HEKMA AI | Free to patients |
πTrial Outcome Tracker | Free to patients |
πDigital Diary | Free to patients |
UAE & Arabic-Language Support
HEKMA is the only clinical trial platform with a native Arabic-language interface built for Gulf patients. UAE-based PAGs get dedicated support, localised regulatory guidance, and access to a patient community that no other platform reaches.
Arab Health Forum
Ω ΩΨͺΨ―Ω Ψ΅ΨΩ ΩΩΩ Ψ±ΨΆΩ Ψ§ΩΨΉΨ±Ψ¨
A multilingual community for patients across the Gulf β supporting Epilepsy, Diabetes, Rare Diseases, and Cardiovascular conditions in Arabic, English, and Urdu.
Trust & Independence Statement
"Our revenue comes from sponsors. Our mission comes from patients and PAGs. We publish all PAG flags β regardless of sponsor response. We have never removed a flag at a sponsor's request. We never will."
HEKMA operates a permanent conflict-of-interest firewall between our commercial sponsor relationships and our PAG accountability tools. PAG flags are immutable records. Sponsor silence is published. No commercial relationship has ever influenced what a patient or PAG sees on this platform.
Security & Privacy
PAG members who connect with trials through HEKMA are protected under the same enterprise security framework used by clinical sponsors and CROs worldwide.
Learn About Data ProtectionHIPAA Compliant
Protected health information safeguards
GDPR Ready
EU data subject rights & cross-border transfers
SOC 2 Type II
Annual third-party security audit
ISO 27001
Information security management standard
UAE PDPL
UAE Personal Data Protection Law
21 CFR Part 11
FDA electronic records & audit trails
ICH GCP E6(R3)
Good Clinical Practice β current revision
Privacy by Design
Data minimisation built into architecture
Pricing
Core PAG tools are permanently free. HEKMA is sponsor-funded. PAGs are never billed for the tools that serve their members.
All PAGs β always
Β£0 / $0 / AED 0
Permanently free. Sponsor-funded.
Most Popular
Growing PAGs wanting deeper insight
Sponsor-subsidised
Contact us β PAGs are never billed directly
National / international PAGs
Custom partnership
Strategic partnerships β contact the PAG team
Join HEKMA
Free to register. No credit card. No obligation. Our PAG partnerships team will be in touch within 2 business days.
